Challenge in treating COVID-19 associate pulmonary aspergillosis: Supratherapeutic voriconazole levels

Letter suggests in severe COVID-19 patients with high-level inflammation, risk of voriconazole toxicity may be higher. The fact trough level does not decrease despite reduction of dose could be explained by decrease in hepatic clearance due to genetic polymorphism or inflammation

British Journal of Clinical Pharmacology